Sonoma Pharmaceuticals, Inc. (SNOA) Stock Price & Analysis
Sonoma Pharmaceuticals, Inc. (SNOA) rose 1.83% to USD 1.11 as of June 10, 2026 at 02:32 UTC, according to Nexqual real-time market data.
SNOA last closed at USD 1.09; the session ranged USD 1.07–1.17 on volume of 75,257 shares. Market capitalization is $3.86M, with a 52-week range of USD 0.85–6.92 (NCM). Source: Nexqual, June 10, 2026 at 02:32 UTC.
Key Statistics (as of June 10, 2026 at 02:32 UTC)
| Price | USD 1.11 |
|---|---|
| Change | ▲ 1.83% (up) |
| Previous Close | USD 1.09 |
| Open | USD 1.09 |
| Day Range | USD 1.07 – 1.17 |
| 52-Week Range | USD 0.85 – 6.92 |
| Volume | 75,257 shares |
| Market Cap | $3.86M |
| Exchange | NCM |
Technical Analysis (SNOA)
Nexqual's technical model rates SNOA "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:32 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 33.18 (neutral) |
| vs SMA50 | Below (USD 1.54) |
| MACD | -0.09 (negative) |
Analyst Ratings (SNOA)
Wall Street analysts rate SNOA "None", per Nexqual as of June 10, 2026 at 02:32 UTC.
| Consensus Rating | None |
|---|
Earnings (SNOA)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.48 vs est -0.29 ▼ miss |
| 2025-09-30 | USD -0.32 vs est -0.31 ▼ miss |
| 2025-06-30 | USD -0.76 vs est -0.51 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:32 UTC.
Financials & Fundamentals (SNOA)
| Total Revenue | $17.72M |
|---|---|
| Revenue Growth (YoY) | +22.00% |
| Gross Margin | +38.16% |
| Operating Margin | -15.59% |
| Profit Margin | -19.02% |
| ROE | -81.18% |
| Debt / Equity | 19.09 |
| Current Ratio | 2.88 |
| Total Cash | $2.56M |
| Total Debt | $655,000 |
| Free Cash Flow | $-3.57M |
Source: Nexqual, June 10, 2026 at 02:32 UTC.
Financial Health Score (SNOA)
Nexqual rates Sonoma Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:32 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $3M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$4M |
| Efficiency | Critical — ROE -81%, ROA -12.7% |
Ownership (SNOA)
| Insider Ownership | +0.57% |
|---|---|
| Institutional Ownership | +1.97% |
| Shares Outstanding | 3.47M |
| Float | 1.72M |
| Short % of Float | +1.31% |
Source: Nexqual, June 10, 2026 at 02:32 UTC.
Leadership (SNOA)
Sonoma Pharmaceuticals, Inc. is led by Amy M. Trombly Esq. (age 57), CEO, President & Director, per Nexqual as of June 10, 2026 at 02:32 UTC.
| CEO, President & Director | Amy M. Trombly Esq. (age 57) |
|---|---|
| Chief Financial Officer | Jerome J. Dvonch (age 57) |
| Senior Vice President of Regulatory, Quality & Product Development | Arturo Angel |
Major Backers & Investors (SNOA)
Notable institutional backers of Sonoma Pharmaceuticals, Inc. include Fidelity, DRW Securities, LLC, McKinley Carter Wealth Services, Inc., according to Nexqual as of June 10, 2026 at 02:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.54% |
| DRW Securities, LLC | 0.35% |
| McKinley Carter Wealth Services, Inc. | 0.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.08% |
| Geode Capital | 0.57% |
Source: Nexqual, June 10, 2026 at 02:32 UTC.
From Sonoma Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2025-06-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.
- It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel.
- The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product.
- In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▲ 1.89% |
| VRPX | Virpax Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| EDSA | Edesa Biotech, Inc. | USD 4.94 | ▼ 9.52% |
| ADTX | Aditxt, Inc. | USD 0.03 | ▼ 53.39% |
| WORX | SCWorx Corp. | USD 0.26 | ▼ 24.43% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:32 UTC. This page is informational and not investment advice.